LOGICBIO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Di
LOGICBIO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against LogicBio Therapeutics, Inc.
LEAD PLAINTIFF DEADLINE IS MAY 18, 2020
PR Newswire
NEW YORK, March 27, 2020
NEW YORK, March 27, 2020 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed against of LogicBio Therapeutics, Inc. ("LogicBio" or the Company") (NASDAQ: LOGC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired LogicBio securities between December 3, 2018 and February 10, 2020, inclusive (the "Class Period").
All investors who purchased shares of LogicBio Therapeutics, Inc. and incurred losses are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com.
If you have incurred losses in the shares of LogicBio Therapeutics, Inc., you may, no later than May 18, 2020, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of LogicBio Therapeutics, Inc.
## Follow the firm and learn about newly filed cases on Twitter and Facebook ##
The filed Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements that:
- LogicBio Therapeutics, Inc.'s behind-schedule and rushed Investigational New Drug ("IND") submission of LB-001 did not answer certain pertinent clinical and nonclinical questions;
- as a result, the U.S. Food and Drug Administration was likely to hold or deny the IND submission of LB-001 for treatment of methylmalonic academia (MMA); and
- as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content to download multimedia:http://www.prnewswire.com/news-releases/logicbio-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman--herz-llp-announces-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-the-district-of-new-jersey-against-l-301031041.html
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.